CDR-Life

Meet Fabian Scheifele, Head of Discovery at CDR-Life 🧬 For 7+ years, he's led our Discovery team with passion—and moonlighted as our office egg dealer 🥚🚐 Fresh science, fresh eggs, and a love for the outdoors! #TeamTuesday #CDRLife

Check out our posters on T-cell engagers for solid tumors at #AACR2025 Chicago: CDR404 (MAGE‑A4) – more potent with less T-cell exhaustion than a direct competitor (Abs #3494) CDR505 (KK‑LC‑1) – first‑in‑class, highly specific and potent (Abs #3493) bit.ly/4jMGAeb

Say hello to Sophie Barsin, our Portfolio Management expert! Her unique perspective complements our scientists' expertise, creating a balanced approach that drives project success and helps guides promising research toward meaningful outcomes. Learn more cdr-life.com

Pipeline Expansion: CDR111, novel trispecific molecule for immune reset in autoimmune diseases! Plus, oncology updates at #AACR25! Join us on April 28 for TCE data: · CDR404 – Potential best-in-class MAGE-A4 TCE · Novel TCE for HLA-A*01/KK-LC-1 tumors bit.ly/43UTVfM

#InternationalWomensDay! At CDR-Life, we’re inspiring the next generation of scientists. Our team visited Neue Schule Zürich to share career paths, teamwork and the science behind our work. We loved meeting future female scientists!

Heading to Milan for BIO-Europe Spring! Our Chief Business Officer Sarah Holland will share insights on the future of T cell engagers in cancer and autoimmune disease treatment—plus what’s ahead for our innovative M-gager® platform. Let’s connect! #BIOEuropeSpring #TCellEngagers

Thank you Modern Retina for covering the progress of our collaboration w Boehringer Ingelheim. We’ve reached our 5th milestone as BI 771716, our antibody fragment technology, advances into Ph 2 trials for geographic atrophy. Patient enrollment is underway! modernretina.com/view/cdr-life-…

Proud to have our CBO Sarah Holland chair the Pharma Dealmakers Panel at the #Sachs_ELSF alongside leaders from @Novartis, @Roche, @GSK, @Sanofi & @Secarna discussing the future of biotech partnerships

Excited to hold our first Autoimmune Scientific Advisory Board meeting today! With CDR404's clinical progress & our new CDR111 (CD3xCD19xBCMA trispecific) for immune reset, our proprietary antibody-based M-gager® platform expands our unique T cell engager approach to autoimmunity

Meet Ivana Tosevski, our Head of Preclinical Safety! Ivana plays a crucial role in ensuring the safety of our molecules before they advance to clinical trials. Thank you, Ivana, for being an integral member of the CDR-Life family! Learn more about us at cdr-life.com

Biotech new year kicks off in SF! 🌉 Heading to #JPM2025 to discuss T cell engagers – an exciting approach for cancer & autoimmune therapies via our unique M-gager® platform. Reach out to chat.

Science + People = Magic! David Stocker embodies CDR-Life's spirit. 3 years of great work in therapeutic development. Discover more about our incredible team and science: cdr-life.com

Expanding our leadership team! Sarah Holland joins CDR-Life as Chief Business Officer to drive our M-gager® platform and T cell engager therapies forward. Excited to accelerate our impact in cancer and autoimmune disease treatment. Full details: #latest" target="_blank" rel="nofollow noopener">cdr-life.com/news/#latest

Geneva-bound! CDR-Life at #ESMOIO, showcasing M-gager® and CDR404 – our novel T cell engager targeting MAGE-A4 in solid tumors. Let's connect! #ESMOImmuno24

Behind game-changing clinical trials is an outstanding leader. Meet Clare Price, VP of Clinical Operations! She's advancing our M-gager platform and T cell engager therapies through expert trial management and unwavering dedication to patient safety. cdr-life.com

Looking forward to @Jefferies London Healthcare Conference! CEO Christian Leisner and CFO Konstantin von Schulthess will discuss CDR-Life's innovative T cell engager platform targeting hard-to-treat solid cancers and autoimmune diseases. Let's connect! #JefferiesHealthcare

Join us at #SITC2024! We're presenting a poster on CDR404, our innovative T cell engager targeting MAGE-A4 in solid tumors such as lung, bladder & head/neck cancers. Stop by our poster or reach out to connect!

Meet Stephanie Jungmichel, our Head of Pharmacology! Leading our cell biology research, she drives the development of our T cell engagers (M-gager®) from discovery to clinic. First in our series introducing the brilliant minds behind CDR-Life!

Stockholm calling! CDR-Life CEO Christian Leisner is attending #BIOEurope discussing the company’s M-gager portfolio for solid tumors and autoimmune diseases and T cell engager therapeutics pipeline. Drop us a line if you want to connect!

It was a pleasure speaking with @Brad Loncar about our T cell engager (TCE) platform to target hard-to-treat tumors. Check out the full interview to learn about our pipeline and upcoming milestones.